[研究报告] 阿尔茨海默氏症药物市场预计将从 2022 年的 62.1 亿美元增长到 2030 年的 220.1 亿美元;预计 2022-2030 年期间的复合年增长率为 17.1%。
市场洞察和分析师观点:
阿尔茨海默病 (AD) 是一种由神经元逐渐死亡引起的神经系统疾病。症状逐渐出现,并可能导致痴呆。虽然这种疾病无法完全治愈,但有些药物可以暂时缓解症状并减缓疾病的进展。AD 患病率高,尤其是在老年人群体中,制药行业为引进针对该疾病的诊断和治疗方法而开展的研发活动不断增加,是推动阿尔茨海默病药物市场增长的关键因素。然而,药物的副作用和严格的监管环境阻碍了市场的发展。此外,人们对 AD 个性化治疗和精准药物的日益关注预计将在未来几年带来新的阿尔茨海默病药物市场趋势。
增长动力和限制因素:
阿尔茨海默病和相关痴呆症病例的增加推动了阿尔茨海默病药物市场规模的增长。阿尔茨海默病是全世界最常见的痴呆症,占所有病例的 60-70%。它是一种渐进性的神经退行性疾病,多年来病情逐渐恶化,在老龄化人口中更为常见。根据世界卫生组织 (WHO) 于 2022 年 10 月发布的报告,到 2030 年,全球 60 岁及以上人口将增长到 14 亿,到 2050 年将达到 21 亿。预计这一不断增长的老年人口将增加疾病负担,从而促进未来几年对相关医疗治疗的需求。
此外,人们对 AD 的认识不断提高、诊断率不断提高以及对新疗法开发的投资不断增加,这些都是市场增长的推动因素。根据阿尔茨海默病协会 2021 年发布的一份报告,该协会在 2020 年投资了 6300 万美元,用于推进阿尔茨海默病和痴呆症的研究。
然而,潜在的副作用对阿尔茨海默氏症药物市场的发展具有重大影响。乙酰胆碱酯酶抑制剂 (AChEIs) 和 NMDA 受体拮抗剂是常用于治疗 AD 的一类药物。尽管这些药物被广泛使用,并且按指示使用时被认为是一般安全的,但它们的使用存在一些特定的副作用和担忧。与 AD 药物相关的最显著的不良反应是服用过量或使用不当时出现头晕、恶心、腹泻和腹痛。这是一个主要问题,可能会影响消费者对产品的信心,从而导致使用量下降。根据 ScienceDirect Journal 于 2021 年发表的一篇文章,为评估用于治疗 AD 的药物的不良反应而进行的研究报告了与 AChEIs 相关的心脏不良事件和与美金刚相关的胃肠道副作用,如便秘、腹泻、呕吐和腹痛。因此,这些药物的副作用阻碍了阿尔茨海默氏症药物市场的发展。
定制此报告以满足您的需求
您可以免费定制任何报告,包括本报告的部分内容、国家级分析、Excel 数据包,以及为初创企业和大学提供优惠和折扣
- 获取此报告的关键市场趋势。这个免费样品将包括数据分析,从市场趋势到估计和预测。
报告细分和范围:
“阿尔茨海默氏症药物市场分析”是通过考虑以下部分进行的:药物类别和分销渠道。
节段分析:
根据药物类别,市场细分为胆碱酯酶抑制剂、NMDA 受体拮抗剂、组合药物和在研药物。胆碱酯酶抑制剂部分在 2022 年占据了阿尔茨海默病药物市场的最大份额。在研药物部分预计在 2022-2030 年期间的复合年增长率最高。胆碱酯酶抑制剂部分进一步细分为多奈哌齐、加兰他敏和利凡斯的明。胆碱酯酶抑制剂由精神科医生或神经科医生等专家为早期至中期 AD 开具处方。这些药物可提高大脑中乙酰胆碱的水平,乙酰胆碱是一种帮助神经细胞相互交流的神经递质。
根据分销渠道,市场分为医院药房、零售药房和在线药房。2022 年,医院药房占据阿尔茨海默病药物市场的最大份额。预计在线药房市场在 2022-2030 年期间的复合年增长率最高。
区域分析:
阿尔茨海默氏症药物市场报告的范围包括北美、欧洲、亚太地区、南美和中美以及中东和非洲。2022 年,由于制药公司开展了广泛的研发活动,以及该地区老龄人口中 AD 和相关痴呆症的流行,北美占据了全球市场的最大份额。根据阿尔茨海默氏症协会的数据,2023 年,美国有超过 600 万人被诊断出患有 AD,65 岁或以上的人中约有 1/9 患有阿尔茨海默氏症,占美国人口的 10.7%。此外,根据美国疾病控制和预防中心 (CDC) 2020 年 10 月提供的数据,AD 是美国成年人第六大死亡原因。此外,美国各地医疗服务支出的增加推动了对 AD 治疗药物的需求,有利于该地区阿尔茨海默氏症药物市场的增长。
阿尔茨海默氏症药物市场报告范围
行业发展和未来机遇:
阿尔茨海默症药物市场预测可以帮助该市场的利益相关者制定增长战略。以下列出了全球阿尔茨海默症药物市场的主要参与者采取的一些举措:
- 2024年1月,卫材株式会社与Biogen Inc.宣布,双方合作开发的LEQEMBI在中国获得分销许可,这是一种人源化的抗可溶性聚集性淀粉样β蛋白(Aβ)单克隆抗体,开发用于治疗AD引起的轻度认知障碍(MCI)和轻度AD痴呆症。
- 2023年5月,大冢制药株式会社与Lundbeck LLC宣布,双方合作开发的含brexpiprazole的REXULTI补充新药申请(sNDA)获得美国食品药品监督管理局(FDA)批准,用于治疗阿尔茨海默病和痴呆症的神经精神症状。
- 2023年5月,礼来公司宣布其阿尔茨海默病药物Donanemab的TRAILBLAZER-ALZ 2第3期研究取得了积极成果。根据该研究,Donanemab显著减缓了早期症状性AD患者的认知和功能衰退。
- 2022 年 9 月,Corium, Inc. 在美国推出了多奈哌齐透皮系统 ADLARITY。这是一种处方药,旨在治疗 AD 患者的轻度、中度或重度痴呆症。该透皮系统是第一个也是唯一一个每周使用一次的贴剂,可通过皮肤输送稳定剂量的多奈哌齐,并且没有胃肠道副作用。
竞争格局和重点公司:
辉瑞公司、西门子医疗有限公司、梯瓦制药工业有限公司、葛兰素史克公司、赛诺菲、诺华公司、阿斯利康、艾伯维公司、卫材株式会社和武田制药有限公司是阿尔茨海默病药物市场报告中介绍的知名企业。此外,在研究过程中还研究和分析了其他几家企业,以全面了解市场及其生态系统。
报告范围
阿尔茨海默氏症药物市场区域洞察
Insight Partners 的分析师已详尽解释了预测期内影响阿尔茨海默氏症药物市场的区域趋势和因素。本节还讨论了北美、欧洲、亚太地区、中东和非洲以及南美洲和中美洲的阿尔茨海默氏症药物市场细分和地理位置。
- 获取阿尔茨海默氏症药物市场的区域特定数据
阿尔茨海默氏症药物市场报告范围
报告属性 | 细节 |
---|---|
2022 年市场规模 | 62.1亿美元 |
2030 年的市场规模 | 220.1亿美元 |
全球复合年增长率(2022 - 2030 年) | 17.1% |
史料 | 2020-2022 |
预测期 | 2022-2030 |
涵盖的领域 | 按药品类别
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
阿尔茨海默氏症药物市场参与者密度:了解其对业务动态的影响
阿尔茨海默症药物市场正在快速增长,这得益于终端用户需求的不断增长,这些需求源于消费者偏好的不断变化、技术进步以及对产品优势的认识不断提高等因素。随着需求的增加,企业正在扩大其产品范围,进行创新以满足消费者的需求,并利用新兴趋势,从而进一步推动市场增长。
市场参与者密度是指在特定市场或行业内运营的企业或公司的分布情况。它表明在给定市场空间中,相对于其规模或总市场价值,有多少竞争对手(市场参与者)存在。
在阿尔茨海默氏症药物市场运营的主要公司有:
- 辉瑞公司
- 西门子医疗保健有限公司
- 梯瓦制药工业有限公司
- 葛兰素史克公司
- 赛诺菲
免责声明:上面列出的公司没有按照任何特定顺序排列。
- 了解阿尔茨海默氏症药物市场的主要参与者概况
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Key factors driving the Alzheimer’s drugs market growth include the high prevalence of AD, particularly in the senior population, and growing research and development activities in the pharmaceutical industry to introduce diagnostics and therapies for the condition.
The Alzheimer’s drugs market was valued at US$ 6.21 billion in 2022.
The Alzheimer’s drugs market is expected to be valued at US$ 22.01 billion in 2030.
Alzheimer's disease (AD) is a neurological disorder caused by the progressive death of neurons. The symptoms begin gradually and can lead to dementia. Although the condition cannot be cured completely, there are medicines available that can temporarily alleviate the symptoms and slow down the progression of the disease. Drugs from the class of cholinesterase inhibitors, NMDA receptor antagonists, and combination of these two are indicated for AD.
The Alzheimer’s drugs market, by drug class, is segmented into cholinesterase inhibitors, NMDA receptor antagonists, combination drugs, and pipeline drugs. The cholinesterase inhibitors segment held a larger market share in 2022. The pipeline drugs segment is anticipated to register a higher CAGR during 2022-2030.
The Alzheimer’s drugs market majorly consists of the players such as Pfizer Inc.; Siemens Healthcare GmbH; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline plc; Sanofi; Novartis AG; AstraZeneca; AbbVie Inc.; Eisai Co., Ltd.; and Takeda Pharmaceutical Company Limited.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Alzheimer’s Drugs Market
- Pfizer Inc.
- Siemens Healthcare GmbH
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Sanofi
- Novartis AG
- AstraZeneca
- AbbVie Inc.
- Eisai Co., Ltd.
- Takeda Pharmaceutical Company Limited
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.